United Therapeutics (NASDAQ:UTHR) Given New $600.00 Price Target at HC Wainwright

United Therapeutics (NASDAQ:UTHR) had its target price upped by HC Wainwright from $525.00 to $600.00 in a research note issued on Thursday, Marketbeat.com reports. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s target price would indicate a potential upside of 19.20% from the company’s current price.

UTHR has been the topic of a number of other reports. Royal Bank Of Canada raised their price objective on United Therapeutics from $587.00 to $643.00 and gave the company an “outperform” rating in a report on Thursday. Morgan Stanley set a $447.00 target price on United Therapeutics in a report on Wednesday, October 29th. Oppenheimer boosted their price objective on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday. Bank of America restated a “neutral” rating on shares of United Therapeutics in a report on Wednesday. Finally, UBS Group reaffirmed a “buy” rating on shares of United Therapeutics in a research note on Tuesday, February 17th. Nine equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $533.55.

United Therapeutics Trading Down 5.9%

Shares of United Therapeutics stock traded down $31.76 during trading on Thursday, hitting $503.35. The stock had a trading volume of 342,416 shares, compared to its average volume of 346,632. United Therapeutics has a 12 month low of $266.98 and a 12 month high of $537.19. The business’s 50-day moving average is $484.71 and its 200 day moving average is $444.09. The firm has a market cap of $21.67 billion, a price-to-earnings ratio of 19.07, a P/E/G ratio of 2.52 and a beta of 0.85.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.78 by $0.92. The business had revenue of $790.20 million during the quarter, compared to analyst estimates of $814.80 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. United Therapeutics’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same period in the previous year, the business posted $6.19 earnings per share. As a group, equities analysts expect that United Therapeutics will post 24.48 EPS for the current year.

Insider Activity

In other United Therapeutics news, COO Michael Benkowitz sold 14,440 shares of the company’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $472.13, for a total value of $6,817,557.20. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Christopher Causey sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an average price of $520.00, for a total value of $520,000.00. Following the completion of the sale, the director directly owned 4,190 shares in the company, valued at approximately $2,178,800. This represents a 19.27% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 411,954 shares of company stock worth $199,552,088. Corporate insiders own 10.30% of the company’s stock.

Hedge Funds Weigh In On United Therapeutics

Several hedge funds have recently modified their holdings of the stock. Wellington Management Group LLP boosted its holdings in shares of United Therapeutics by 74.5% during the 4th quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after purchasing an additional 1,042,711 shares during the last quarter. Darwin Global Management Ltd. bought a new stake in United Therapeutics during the 3rd quarter valued at $317,617,000. Norges Bank bought a new position in United Therapeutics during the 4th quarter worth about $293,418,000. Invesco Ltd. raised its holdings in shares of United Therapeutics by 90.2% in the 2nd quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock valued at $254,219,000 after purchasing an additional 419,588 shares in the last quarter. Finally, Avoro Capital Advisors LLC boosted its position in United Therapeutics by 17.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock valued at $1,269,803,000 after acquiring an additional 383,838 shares in the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Key Headlines Impacting United Therapeutics

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Q4 EPS beat and record full‑year revenue support the bull case — UTHR reported $7.70 EPS vs. $6.78 expected and full‑year 2025 revenues of $3.18B (11% YoY), which underpinned recent buying interest. BusinessWire press release
• Positive Sentiment: Management set an ambitious target — UTHR is targeting a ~$4B revenue run‑rate by 2027 as several late‑stage and new product launches approach, giving investors a clear growth thesis. Seeking Alpha article
• Positive Sentiment: Analysts raised price targets — RBC and Oppenheimer issued material upside revisions (RBC to $643, Oppenheimer to $600), signaling renewed upside expectations from some institutional research desks. Benzinga coverage
• Positive Sentiment: Unusually heavy call buying around the print indicates bullish options positioning, which can amplify short‑term upside momentum. Zacks options/earnings report
• Neutral Sentiment: Street views remain mixed — several firms maintained Hold/Neutral ratings (BTIG, Morgan Stanley) and some models still show near‑term franchise headwinds despite pipeline upside. TipRanks note
• Neutral Sentiment: Wells Fargo raised its target but kept an Equal‑Weight rating (new $466 target), suggesting limited conviction that the stock will outperform from here. Benzinga coverage
• Negative Sentiment: Revenue missed the quarterly consensus ($790.2M actual vs. ~$814.8M expected), which triggered earlier downside and highlights top‑line execution risk. Investing.com coverage
• Negative Sentiment: Significant insider selling — the COO disclosed multi‑lot sales (including ~14,440 shares) and a director sold shares recently; heavy insider disposals can undermine confidence among some investors. InsiderTrades report

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.